A conditional linear Gaussian network to assess the impact of several agronomic settings on the quality of Tuscan Sangiovese grapes
Biometrical Letters · 2017
DOI: 10.1515/bile-2017-0002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biometrical Letters, 2017. Verfasst von Alessandro Magrini und 2 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
In this paper, a Conditional Linear Gaussian Network (CLGN) model is built for a two-year experiment on Tuscan Sangiovese grapes involving canopy management techniques (number of buds, defoliation and bunch thinning) and harvest time (technological and late harvest). We found that the impact of the considered treatments on the color of wine can be predicted still in the vegetative season of the grapevine; the best treatments to obtain wines with good structure are those with a low number of buds; the best treatments to obtain fresh wines suitable for young consumers are those with technological rather than late harvest, preferably with a high number of buds, and anyway with both defoliation and bunch thinning not performed.
Zitieren
APA
Magrini, A., Blasi, S. D., & Stefanini, F. M. (2017). A conditional linear Gaussian network to assess the impact of several agronomic settings on the quality of Tuscan Sangiovese grapes. Biometrical Letters. https://doi.org/10.1515/bile-2017-0002
Vancouver
Magrini A, Blasi SD, Stefanini FM. A conditional linear Gaussian network to assess the impact of several agronomic settings on the quality of Tuscan Sangiovese grapes. Biometrical Letters. 2017. doi:10.1515/bile-2017-0002
BibTeX
@article{Magrini2017,
author = {Magrini, Alessandro and Blasi, Stefano Di and Stefanini, Federico Mattia},
title = {A conditional linear Gaussian network to assess the impact of several agronomic settings on the quality of Tuscan Sangiovese grapes},
journal = {Biometrical Letters},
year = {2017},
doi = {10.1515/bile-2017-0002}
}
EUVIMED